Home › Funds › SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC › IONS

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC position in IONS

IONIS PHARMACEUTICALS INC · Health Care

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC reported holding 787,263 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$62.4M, representing 1.68% of its reported portfolio and ranking #14 among its reported holdings. SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed IONS holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

Latest position (Q2 2026)787.26K sh
Reported value held$62.42M
Portfolio Weight1.68%
First reportedQ3 2025
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's IONS position evolved

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC first disclosed a stake in IONS in Q3 2025 at 599,100 shares (US$39.2M). The position peaked in Q2 2026 at 787,263 shares, worth US$62.4M. Across 4 filings, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 787,263 shares valued at US$62.4M — an increase of 337,263 shares quarter over quarter.. Notable position changes include a 50% trim in Q4 2025 (shares fell 5% over the following quarter), a 50% increase in Q1 2026 (shares rose 6% over the following quarter), a 75% increase in Q2 2026 (shares fell 44% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 599.10K $39.19M New
Q4 2025 300.00K $23.73M Reduce
Q1 2026 450.00K $33.79M Add
Q2 2026 787.26K $62.42M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About IONS and 13F data

IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 41 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$495.7M), TWO SIGMA ADVISERS, LP (US$241.5M), Tweedy, Browne Co LLC (US$180.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding IONS

All IONS fund holders →

FAQ

How long has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC held IONS?

SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC has disclosed IONS holdings in 4 of the last 4 reported quarters, going back to Q3 2025.

What is SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC's current position in IONS?

As of Q2 2026, SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC holds 787.26K shares of IONS (IONIS PHARMACEUTICALS INC), valued at $62.42M, representing 1.68% of its reported portfolio and ranking #14.

Has SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC been buying or selling IONS?

In the latest 13F filing (Q2 2026), SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC increased its position in IONS. The position peaked in Q2 2026 at 787.26K shares.

Which other funds hold IONS?

Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, Tweedy, Browne Co LLC, among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.